menu
    • menu

    Company profile for Cynata Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson’s group, which included the first successful isolation of human embryonic stem cells i...
    Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). UWM is a world-renowned leader in stem cell research, in particular for the work by Professor James Thomson’s group, which included the first successful isolation of human embryonic stem cells in 1998, and the derivation of induced pluripotent stem cells (iPSCs) from human adult cells in 2007.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cynata TherapeuticsAustralia Flag
    Country
    Country
    Australia
    Address
    Address
    Level 3, 62 Lygon Street CARLTON, VICTORIA 3053
    Telephone
    Telephone
    +61 (0) 412 119 343
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cynata.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cynata-therapeutics?trk=tyah&trkInfo=clickedVertical%3Acompany%2CclickedEntityId%3A3666835%2Cidx%3A1-1-1%2CtarId%3A1453956314446%2Ctas%3Acynata
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/cynatastemcells

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
    Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

    15 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/patient-enrolment-completed-in-phase-2-agvhd-clinical-trial-302641748.html

    PR NEWSWIRE BIO
    15 Dec 2025
    Share Share
    Cynata completes patient in ph1 trial of CYP-006TK in diabetic foot ulcers
    Cynata completes patient in ph1 trial of CYP-006TK in diabetic foot ulcers

    09 Apr 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=168420&sid=2

    PHARMABIZ
    09 Apr 2024
    Share Share
    First Patient Treated in Phase 2 GvHD Trial
    First Patient Treated in Phase 2 GvHD Trial

    04 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/first-patient-treated-in-phase-2-gvhd-trial-302079209.html

    PR NEWSWIRE
    04 Mar 2024
    Share Share
    Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
    Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial

    26 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/encouraging-initial-data-from-cyp-006tk-diabetic-foot-ulcer-clinical-trial-302070709.html

    PR NEWSWIRE
    26 Feb 2024
    Share Share
    US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
    US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD

    26 May 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-clears-ind-for-cynatas-phase-2-clinical-trial-of-cyp-001-in-gvhd-301555847.html

    PRNEWSWIRE
    26 May 2022
    Share Share
    Cynata secures manufacturing deal for breakthrough biotech
    Cynata secures manufacturing deal for breakthrough biotech

    29 Dec 2021

    // THEWEST

    https://thewest.com.au/business/public-companies/cynata-secures-manufacturing-deal-for-breakthrough-biotech-c-5119020

    THEWEST
    29 Dec 2021
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search